Cyclerion Therapeutics, Inc. (KRSA) – What Are Researchers Thinking About This Stock?

Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) has earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $53.00.

A number of analysts recently issued reports on KRSA shares. Wall Street Zen raised Cyclerion Therapeutics to a “sell” rating in a research report on Saturday, October 3rd. Stifel Nicolaus began coverage on Cyclerion Therapeutics in a research note on Monday, September 14th. They set a “buy” rating and a $43.00 price target for the company. TD Cowen began coverage on Cyclerion Therapeutics in a research report on Monday, September 14th. They set a “buy” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Friday, July 24th. Finally, Wedbush initiated coverage on shares of Cyclerion Therapeutics in a research report on Monday, October 5th. They set an “outperform” rating and a $44.00 price target for the company.

Institutional Trading of Cyclerion Therapeutics

Several large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Cyclerion Therapeutics in the 2nd quarter worth approximately $57,000. Braidwell LP bought a new stake in Cyclerion Therapeutics during the second quarter worth approximately $532,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Cyclerion Therapeutics in the second quarter worth about $1,013,000. 75.62% of the stock is currently owned by institutional investors and hedge funds.

Cyclerion Therapeutics Stock Performance

NASDAQ KRSA opened at $30.14 on Wednesday. Cyclerion Therapeutics has a 1 year low of $7.19 and a 1 year high of $59.36. The firm has a market capitalization of $1.37 billion, a P/E ratio of -2.59 and a beta of 1.85.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and cardiopulmonary diseases. The company’s research centered on soluble guanylate cyclase (sGC) stimulators, a class of compounds intended to regulate cellular signaling and potentially address diseases associated with impaired nitric oxide signaling.

Cyclerion was formed in 2019 as a spin-off from Ironwood Pharmaceuticals. Its historical development portfolio included olinciguat, an investigational treatment studied for sickle cell disease, and praliciguat, which was evaluated for conditions including diabetic nephropathy and nonalcoholic steatohepatitis.